- Home
- MXCT
MXCT
MaxCyte Inc.
as 08-28-2025 4:00pm EST
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | ROCKVILLE |
| Market Cap: | 242.4M | IPO Year: | 2021 |
| Target Price: | $7.50 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.42 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.26 - $5.20 | Next Earning Date: | 08-06-2025 |
| Revenue: | $35,754,000 | Revenue Growth: | -21.31% |
| Revenue Growth (this year): | -3.87% | Revenue Growth (next year): | 14.79% |
Stock Insider Trading Activity of MaxCyte Inc. (MXCT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Swirsky Douglas J | MXCT | CHIEF FINANCIAL OFFICER | Aug 13 '25 | Buy | $1.29 | 50,000 | $64,500.00 | 161,811 | |
| DOUGLAS RICHARD | MXCT | N/A | Aug 13 '25 | Buy | $1.39 | 80,000 | $111,040.00 | 230,577 | |
| Erck Stanley C | MXCT | N/A | Aug 13 '25 | Buy | $1.37 | 100,000 | $137,220.00 | 398,328 | |
| Masoud Maher | MXCT | President and CEO | Aug 13 '25 | Buy | $1.37 | 75,000 | $102,915.00 | 175,000 | |
| Brooke William W | MXCT | N/A | Aug 13 '25 | Buy | $1.29 | 50,000 | $64,500.00 | 150,879 | |
| Hemrajani Rekha | MXCT | N/A | Jun 25 '25 | Sell | $2.09 | 10,684 | $22,377.64 | 39,893 |
Latest MaxCyte Inc. News
MXCT Breaking Stock News: Dive into MXCT Ticker-Specific Updates for Smart Investing
MT Newswires
3 months ago
MaxCyte Collaborates With Ori Biotech to Improve Cell Therapy Manufacturing
GlobeNewswire
3 months ago
MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies
Insider Monkey
4 months ago
MaxCyte, Inc. (MXCT): A Bull Case Theory
GuruFocus.com
4 months ago
MaxCyte Inc (MXCT) Q1 2025 Earnings Call Highlights: Strong Revenue Alignment Amidst Growth ...
Zacks
4 months ago
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates
GlobeNewswire
4 months ago
MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance
GlobeNewswire
5 months ago
MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025
Zacks
5 months ago
Down -27.78% in 4 Weeks, Here's Why You Should You Buy the Dip in MaxCyte (MXCT)
Compare MXCT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MXCT MaxCyte Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.